[18F]AlF-HER2-BCH

[18F]AlF-HER2-BCH is a radiopharmaceutical PET imaging tracer developed by Peking University Cancer Hospital (Beijing Cancer Hospital) for the non-invasive quantification of Human Epidermal Growth Factor Receptor 2 (HER2) expression. It consists of a HER2-targeting moiety, typically a nanobody or small protein, labeled with the positron-emitting isotope fluorine-18 (18F) using an aluminum fluoride (AlF) complex. This tracer is designed to provide whole-body molecular profiling of HER2 status, which is critical for managing metastatic breast cancer, particularly in identifying HER2-low expression and biological heterogeneity across different metastatic sites. Clinical studies, such as NCT04547309, have demonstrated its superior diagnostic performance compared to [18F]FDG PET/CT in detecting malignant lesions and its strong correlation with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results.

Other names

18F-AlF-HER2-BCH[18F]AlF-NOTA-HER2-BCH